<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">Tumor lysis syndrome</z:e> (TLS) is a severe life-threatening complication which typically occurs in highly proliferative <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, such as Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> or <z:mpath ids='MPATH_310'>germ cell tumors</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>Although TLS is unusual in <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, it should not be overlooked as it is associated with significant morbidity </plain></SENT>
<SENT sid="2" pm="."><plain>In recent years, emerging new agents such as thalidomide and <z:chebi fb="0" ids="52717">bortezomib</z:chebi> have been found to be highly effective in the treatment of <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>In this milieu, there is greater concern that the rate of TLS in <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> will increase </plain></SENT>
<SENT sid="4" pm="."><plain>We herein report 2 patients with light chain <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> who developed TLS during treatment </plain></SENT>
<SENT sid="5" pm="."><plain>One patient improved after hydration, <z:chebi fb="0" ids="40279">allopurinol</z:chebi> and forced <z:mp ids='MP_0001762'>diuresis</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>The other underwent hemodialysis because of <z:hpo ids='HP_0100520'>oliguria</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>These 2 patients did not have heavy <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burdens </plain></SENT>
<SENT sid="8" pm="."><plain>They also lacked risk factors of TLS that were described in previous reports </plain></SENT>
<SENT sid="9" pm="."><plain>Our experience suggests light chain <z:mp ids='MP_0009440'>myeloma</z:mp> with underlying <z:mp ids='MP_0009440'>myeloma</z:mp> kidney is associated with a risk of TLS </plain></SENT>
<SENT sid="10" pm="."><plain>Clinical awareness, close monitoring and early intervention are the keystones in the management of these patients </plain></SENT>
</text></document>